The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: A meta-analysis

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 533-541

  Grammatikos, G ^a   Farnik, H ^a   Bon, D ^b   Bohlig A ^c   Bader, T ^d   Berg, T ^c   Zeuzem, S ^a   Herrmann, E ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

antiviral; bezafibrate; cholesterol; dyslipidemia; hepatitis C virus; statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PEGINTERFERON; RIBAVIRIN; ROSUVASTATIN; SIMVASTATIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; VIRUS LOAD; BLOOD; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

BEZAFIBRATE; HEPATITIS C, CHRONIC; HUMANS; HYPOLIPIDEMIC AGENTS; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903814596     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12274     Document Type: Article

References (50)

1. Neal KR, Ramsay S, Thomson BJ, et al,. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-1104. (Pubitemid 47123240)
2. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
3. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
4. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Berg T, Weich V, Teuber G, et al,. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50: 369-377.
6. Weich V, Herrmann E, Chung TL, et al,. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol 2011; 46: 1427-1436.
7. Lee S, Varano J, Flexman JP, et al,. Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Dis Markers 2010; 28: 273-280.
8. Lange CM, Kutalik Z, Morikawa K, et al,. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 2012; 55: 1038-1047.
9. Akuta N, Suzuki F, Kawamura Y, et al,. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410. (Pubitemid 46185701)
10. Gopal K, Johnson TC, Gopal S, et al,. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-340. (Pubitemid 44214872)
11. Lange CM, von WM, Bojunga J, et al,. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol 2010; 22: 1303-1307.
12. Ramcharran D, Wahed AS, Conjeevaram HS, et al,. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-863.
13. Villa E, Karampatou A, Camma C, et al,. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140: 818-829.
14. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
15. Ye J,. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007; 3: e108.
16. Syed GH, Amako Y, Siddiqui A,. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21: 33-40.
17. Corey KE, Kane E, Munroe C, et al,. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50: 1030-1037.
18. Delang L, Paeshuyse J, Vliegen I, et al,. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
19. Ikeda M, Abe K, Yamada M, et al,. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125. (Pubitemid 44049145)
20. Ye J, Wang C, Sumpter R, et al,. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-15870. (Pubitemid 38021081)
21. Kapadia SB, Chisari FV,. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-2566. (Pubitemid 40279416)
22. Forde KA, Law C, O'Flynn R, et al,. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15: 5020-5027.
23. Harrison SA, Rossaro L, Hu KQ, et al,. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874.
24. Tleyjeh IM, Kashour T, Hakim FA, et al,. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
25. Milazzo L, Caramma I, Mazzali C, et al,. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010; 65: 735-740.
26. Sezaki H, Suzuki F, Akuta N, et al,. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-48.
27. Rao GA, Pandya PK,. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140: 144-152.
28. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
29. Higgins JP, Thompson SG, Deeks JJ, et al,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
30. Egger M, Davey SG, Schneider M, et al,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
31. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
32. Bader T, Fazili J, Madhoun M, et al,. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-1389. (Pubitemid 351813920)
33. Mihaila R, Nedelcu L, Fratila O, et al,. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology 2009; 56: 1704-1709.
34. Mihaila RG, Nedelcu L, Fratila O, et al,. Effects of simvastatin in patients with viral chronic hepatitis C. Hepatogastroenterology 2011; 58: 1296-1300.
35. O'Leary JG, Chan JL, McMahon CM, et al,. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45: 895-898. (Pubitemid 46631558)
36. Fujita N, Kaito M, Kai M, et al,. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006; 13: 441-448.
37. Patel K, Jhaveri R, George J, et al,. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 331-337.
38. Bohlig A, Weich V, Biermer M, et al,. 1092. Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotype 1 infection and elevated gGT levels [Abstract]. J Hepatol 2012; 56: S429-S430.
39. Fujita N, Kaito M, Tanaka H, et al,. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 2280. (Pubitemid 39524721)
40. Kurihara T, Niimi A, Maeda A, et al,. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. Am J Gastroenterol 2001; 96: 1659-1660. (Pubitemid 32455123)
41. Blanchet M, Seidah NG, Labonte P,. SKI-1/S1P inhibition: a promising surrogate to statins to block hepatitis C virus replication. Antiviral Res 2012; 95: 159-166.
42. Sheridan DA, Neely RD, Bassendine MF,. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol 2013; 37: 10-16.
43. Lyn RK, Kennedy DC, Sagan SM, et al,. Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. Virology 2009; 394: 130-142.
44. Kanda T, Yokosuka O, Imazeki F, et al,. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004; 11: 479-487. (Pubitemid 39486611)
45. Krey G, Braissant O, L'Horset F, et al,. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 779-791. (Pubitemid 27225305)
46. Agriesti F, Tataranni T, Ruggieri V, et al,. PPARs and HCV-Related Hepatocarcinoma: a Mitochondrial Point of View. PPAR Res 2012; 2012: 605302.
47. Jiang L, Gu Y, Ye J, et al,. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol Lett 2012; 34: 2205-2212.
48. Torres DM, Harrison SA,. HCV replication and statin pleotropism: an adjuvant treatment panacea? Am J Gastroenterol 2008; 103: 1390-1392. (Pubitemid 351813936)
49. Bader T, Hughes LD, Fazili J, et al,. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naive genotype 1 hepatitis C patients. J Viral Hepat 2013; 20: 622-627.
50. Zhu Q, Li N, Han Q, et al,. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res 2013; 98: 373-379.